Morphic Therapeutic Announces $80 Million Financing to Advance Next-Generation Oral Integrin Therapeutics through Clinical Proof of Concept

Series B financing led by Omega Funds and Novo Holdings

Financing to enable the initiation of IND-enabling and clinical studies in 2019

WALTHAM, Mass. – September 25, 2018 – Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that it has completed a $80 million Series B financing to fund its two lead programs through clinical proof of concept, and to advance multiple other programs into the clinic. The round was co-led by Omega Funds and Novo Holdings. In connection with their investments, Otello Stampacchia, Ph.D., Managing Director at Omega Funds and Nilesh Kumar, Ph.D., Partner at Novo Ventures have joined Morphic’s Board of Directors. New investors including Invus and EcoR1 Capital, in addition to Morphic’s Series A investors, also participated in the Series B Financing.

“Over the past two years we have made exceptional progress in establishing what we believe is the world’s only broad-based structure enabled integrin drug discovery platform, leveraging insights from the Springer lab,” said Praveen Tipirneni, M.D., President & Chief Executive Officer of Morphic Therapeutic. “With compelling preclinical data across a number of programs, we are accelerating our advance into the clinic. We welcome the support of both new and existing investors, including several crossover investors, in our efforts to advance a new generation of oral integrin drugs to treat a diverse range of diseases that present significant unmet medical needs.”

“The Morphic team’s achievements underscore the value of their foundational collaborations with the Springer lab and Schrödinger,” said Otello Stampacchia, Ph.D., Managing Director at Omega Funds. “We are drawn to Morphic by the clear clinical promise of the company’s platform, and the wide range of patients who stand to benefit from the creation of oral integrin therapeutics. We look forward to supporting Morphic’s progress through clinical development.”

“Morphic’s platform has yielded several novel oral drug candidates targeting integrins in several major indications,” said Nilesh Kumar, Ph.D., Partner at Novo Ventures, a U.S.-based affiliate of and advisor to Novo Holdings. “Led by great science and a strong team they have delivered major milestones in laying the foundation for clinical success and we are excited to support their unique programs and platform.”

About Integrins

Integrins are a ubiquitous family of receptors expressed on the surface of most human cells. Integrin signaling controls a wide range of cellular processes, including cell survival, cell cycle progression, immune system activation, cell differentiation and cell migration. Aberrant signaling contributes to a diverse array of human diseases, including each of Morphic Therapeutic’s focus areas of fibrosis, autoimmune diseases and immuno-oncology.

Research in the Springer laboratory has demonstrated that, historically, compounds designed to turn off integrin activity inadvertently worked to promote it, leading to the subsequent failure of oral drug candidates directed at integrin targets. Morphic is leveraging a process that avoids this historic issue to develop what the company intends to be the first generation of oral integrin therapeutics.

About Morphic Therapeutic

Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on integrin biology breakthroughs from the lab of noted entrepreneur and scientific founder Tim Springer, Morphic has developed an exclusive platform to build on these discoveries, complemented by a partnership with computational chemistry leader Schrödinger, Inc., that facilitates the rapid and iterative design of clinical candidates. For more information, visit


Company contact:
Robert E. Farrell, Jr., VP Finance and Ops and Treasurer

Tom Donovan, Ten Bridge Communications


Scroll to Top

Contact Us

Integrin Partnership: Janssen

Morphic entered a research partnership with Janssen in 2019 to discover inhibitors of undisclosed integrin targets. In 2021, this partnership was expanded to include an antibody activator of an integrin target, extending the application of Morphic’s knowledge of integrin biology into modalities beyond small molecules. The antibody activator program is the focus of our collaboration with Janssen today.

Undisclosed Targets

Morphic is leveraging the MInT Platform to discover therapeutically relevant small molecule inhibitors of targets across the integrin family to treat autoimmune diseases, cancer and fibrotic diseases.

Undisclosed Target for Pulmonary Arterial Hypertension

Morphic is deploying the MInT Platform to create small molecule inhibitors of an undisclosed integrin target for evaluation as a potential treatment for pulmonary arterial hypertension (PAH). PAH is a devastating, usually fatal disease characterized by elevated mean pressures in the pulmonary artery and associated with lung and heart dysfunction. Morphic’s PAH program is in preclinical development.


Morphic is developing small molecule inhibitors of the integrin αvβ8 through a combination immuno-oncology approach for the treatment of solid tumors as well as potential additional indications. αvβ8 is known to activate selective isoforms of TGF-β and Morphic has demonstrated that αvβ8 inhibition can potentiate immune checkpoint blockade and potentially drive responses in checkpoint refractory tumors. Morphic’s αvβ8 inhibitors are in preclinical development.

Next Gen α4β7 Inhibitors

Morphic is developing a family of next generation α4β7 small molecule inhibitors with enhanced attributes using the MInT Platform. These candidates have distinct chemical properties from our first-generation inhibitors with differentiated selectivity, potency, and pharmacokinetic profiles. Morphic’s next generation α4β7 inhibitors are currently in preclinical development.